Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluoro-Willardiine is a synthetic analog of willardiine and a potent, selective agonist of ionotropic glutamate receptors, specifically the AMPA receptor subtypes GluA1 and GluA2. It acts as an orthosteric agonist at these receptors with high affinity and selectivity over other glutamate receptor subtypes such as kainate or NMDA receptors. Fluoro-Willardiine is primarily used in research to study excitatory neurotransmission mediated by AMPA-type glutamate receptors in the central nervous system. It is not approved for clinical use and has no known therapeutic indications[1][3][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluoro-willardiine.